FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021388574> ?p ?o ?g. }

• W2021388574 endingPage "S261" @default.
• W2021388574 startingPage "S251" @default.
• W2021388574 abstract "Background. Epidemiological studies have clearly established that human papillomavirus (HPV) infection is the major risk factor for cervical cancer. Most cervical cancers and pre-cancers are HPV-positive. Not all pre-cancers progress to cancer; a significant number regress. The immunological basis for either spontaneous or treatment-mediated recovery from HPV-associated CIN is not clear. Currently, prophylactic vaccines are successfully inducing antibody responses in HPV negative patients. Therapeutic vaccines for HPV-positive patients with disease are needed. There is a need to understand the immunologic basis for the Cell-Mediated Immune (CMI) response and for histological regression to help the formulation of therapeutic vaccines. Material and methods. Four groups of women were identified for this cross-sectional study of CMI. Group 1 consisted of six women without cytological or histological diagnosis of CIN and with an HPV negative test (CIN(−)/HPV(−)). Group 2 included 31 women with a new histological diagnosis of CIN and HPV positive test (CIN(+)/HPV(+)). Groups 3 and 4 were selected from women who had undergone ablative or excisional treatment for CIN at the colposcopy clinic at least 6 months before the study. The women in groups 3 and 4 were (CIN(+)/HPV(+)) before CIN treatment. Group 3 consisted of 22 women without evidence of recurrence of CIN (Recur(−)), and group 4 included 10 with histological diagnosis of recurrent CIN (Recur(+)). In particular, we investigated CMI responses to synthetic peptides from the E6 and E7 oncoproteins of HPV-16. Results. Compared to patients with disease recurrence (Recur(+), n = 10), the majority of individuals who remained recurrence-free post-treatment (Recur(−), n = 22) exhibited significant proliferative responses to synthetic peptides from the E6 (P = 0.001) and the E7 (P = <0.001). In particular, significant responses were observed with the E6 peptide Q15L (aa 43–57, P = 0.006) and the E7 peptide Q19D (aa 44–62, P = 0.002) in Recur(−) patients but not Recur(+) individuals. Additionally, PBMC from women in the Recur(−) group, but not the Recur(+) group, produced predominantly TH1 cytokines upon stimulation with the peptides Q15L or Q19D. Conclusions. These results indicate an association between significant cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 and recurrence-free survival in HPV patients treated for CIN. We predict that these peptides may be useful as indicators of protective immunity for recovery from CIN and also for potential inclusion in designing immunotherapeutic and immunoprophylactic reagents for HPV-associated CIN." @default.
• W2021388574 created "2016-06-24" @default.
• W2021388574 creator A5007076967 @default.
• W2021388574 creator A5016125241 @default.
• W2021388574 creator A5026010782 @default.
• W2021388574 creator A5088778414 @default.
• W2021388574 date "2005-12-01" @default.
• W2021388574 modified "2023-10-17" @default.
• W2021388574 title "Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study" @default.
• W2021388574 cites W102839499 @default.
• W2021388574 cites W111301829 @default.
• W2021388574 cites W1531831170 @default.
• W2021388574 cites W156003141 @default.
• W2021388574 cites W1826967025 @default.
• W2021388574 cites W1831319429 @default.
• W2021388574 cites W1957890909 @default.
• W2021388574 cites W1969631145 @default.
• W2021388574 cites W1974153555 @default.
• W2021388574 cites W1976213001 @default.
• W2021388574 cites W1978146796 @default.
• W2021388574 cites W1981295342 @default.
• W2021388574 cites W1983187600 @default.
• W2021388574 cites W1993680169 @default.
• W2021388574 cites W1995648581 @default.
• W2021388574 cites W1997729487 @default.
• W2021388574 cites W2004243811 @default.
• W2021388574 cites W2007571522 @default.
• W2021388574 cites W2007606931 @default.
• W2021388574 cites W2008564758 @default.
• W2021388574 cites W2021227385 @default.
• W2021388574 cites W2021438212 @default.
• W2021388574 cites W2024673567 @default.
• W2021388574 cites W2026223457 @default.
• W2021388574 cites W2035705701 @default.
• W2021388574 cites W2036909714 @default.
• W2021388574 cites W2038631717 @default.
• W2021388574 cites W2040868302 @default.
• W2021388574 cites W2049612362 @default.
• W2021388574 cites W2055374705 @default.
• W2021388574 cites W2059072983 @default.
• W2021388574 cites W2062078150 @default.
• W2021388574 cites W2073324000 @default.
• W2021388574 cites W2075183351 @default.
• W2021388574 cites W2084797061 @default.
• W2021388574 cites W2086678451 @default.
• W2021388574 cites W2087955623 @default.
• W2021388574 cites W2089899954 @default.
• W2021388574 cites W2091772630 @default.
• W2021388574 cites W2094954825 @default.
• W2021388574 cites W2095317270 @default.
• W2021388574 cites W2095903414 @default.
• W2021388574 cites W2103867211 @default.
• W2021388574 cites W2106510927 @default.
• W2021388574 cites W2107079403 @default.
• W2021388574 cites W2109347835 @default.
• W2021388574 cites W2121679347 @default.
• W2021388574 cites W2124174386 @default.
• W2021388574 cites W2128737857 @default.
• W2021388574 cites W2132494218 @default.
• W2021388574 cites W2136111158 @default.
• W2021388574 cites W2144120532 @default.
• W2021388574 cites W2165877898 @default.
• W2021388574 cites W2169143877 @default.
• W2021388574 cites W2320556745 @default.
• W2021388574 cites W3128343078 @default.
• W2021388574 cites W4255551825 @default.
• W2021388574 cites W4361868650 @default.
• W2021388574 doi "https://doi.org/10.1016/j.ygyno.2005.07.099" @default.
• W2021388574 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16188303" @default.
• W2021388574 hasPublicationYear "2005" @default.
• W2021388574 type Work @default.
• W2021388574 sameAs 2021388574 @default.
• W2021388574 citedByCount "39" @default.
• W2021388574 countsByYear W20213885742012 @default.
• W2021388574 countsByYear W20213885742013 @default.
• W2021388574 countsByYear W20213885742015 @default.
• W2021388574 countsByYear W20213885742017 @default.
• W2021388574 countsByYear W20213885742018 @default.
• W2021388574 countsByYear W20213885742019 @default.
• W2021388574 countsByYear W20213885742022 @default.
• W2021388574 crossrefType "journal-article" @default.
• W2021388574 hasAuthorship W2021388574A5007076967 @default.
• W2021388574 hasAuthorship W2021388574A5016125241 @default.
• W2021388574 hasAuthorship W2021388574A5026010782 @default.
• W2021388574 hasAuthorship W2021388574A5088778414 @default.
• W2021388574 hasConcept C121608353 @default.
• W2021388574 hasConcept C126322002 @default.
• W2021388574 hasConcept C143998085 @default.
• W2021388574 hasConcept C203014093 @default.
• W2021388574 hasConcept C2776117191 @default.
• W2021388574 hasConcept C2777343196 @default.
• W2021388574 hasConcept C2778220009 @default.
• W2021388574 hasConcept C2778580637 @default.
• W2021388574 hasConcept C2779134260 @default.
• W2021388574 hasConcept C29456083 @default.
• W2021388574 hasConcept C71924100 @default.
• W2021388574 hasConcept C8891405 @default.
• W2021388574 hasConcept C90924648 @default.

• next